Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 494

Results For "LA"

8967 News Found

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
Clinical Trials | August 15, 2024

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll

The clinical trial will be conducted at 19 sites with 10,335 participants across India


Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report
Digitisation | August 15, 2024

Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report

Majority of organizations are looking to increase investments in public and hybrid cloud


NHA and MUHS sign MoU to drive digital health education
News | August 14, 2024

NHA and MUHS sign MoU to drive digital health education

The partnership marks a significant milestone in integrating digital health education into medical curricula


Marksans Pharma Q1 FY25 revenue up 18%
News | August 14, 2024

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%


Wanbury appoints Prakash Venkatraman as President of API Business
People | August 14, 2024

Wanbury appoints Prakash Venkatraman as President of API Business

He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years


Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
Opinion | August 14, 2024

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024


HealthCRED secures US$ 1.2 million in seed funding
Startup | August 13, 2024

HealthCRED secures US$ 1.2 million in seed funding

The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service


Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
News | August 13, 2024

Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24


Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
Clinical Trials | August 13, 2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV


Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Drug Approval | August 13, 2024

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years